Microprocessor feet improve prosthetic mobility and physical function relative to non-microprocessor feet

Eric L Weber1, Phillip M Stevens1,2, Dwiesha L England1, Vahness D Swilley1 and Shane R Wurdeman1,3

Abstract

Introduction: The clinical benefits associated with the microprocessor regulation of prosthetic ankle position and resistance have largely been reported through manufacturer conducted research in controlled laboratory environments. Measures with greater ecological validity are needed. This study aimed to understand if there are differences in physical function and mobility outcomes as patients transitioned from a non-Microprocessor to Microprocessor Feet.

Method: A retrospective analysis of patient outcomes was performed. Patient-reported benefits associated with the adoption of such prosthetic foot-ankle mechanisms were collected from 23 individuals through the longitudinal use of a custom short form of the Patient-Reported Outcomes Measurement Information System-Physical Function and individual items from the Prosthesis Evaluation Questionnaire.

Results: The impact of Microprocessor Feet upon physical function and mobility were observed in a significant increase in physical function (mean increase in t-score of 5.4 ± 1.25; \( p = .0004 \)) and significant improvements in several mobility items.

Conclusions: Collectively, these measures support the beneficial impact of Microprocessor Feet on improving socket comfort, reducing back pain, improving sit to stand transfers and enhancing hill ascent and descent as well as stair negotiation.

Keywords

Patient reported outcomes measurement information system, prosthesis evaluation questionnaire, microprocessor feet, lower limb prosthesis, amputation

Date received: 24 March 2022; accepted: 27 June 2022

Introduction

Microprocessor regulation of prosthetic ankle position and resistance to movement was introduced commercially in 2006. Since that time, a number of distinct approaches to such regulation have been introduced to the field and explored in the literature. Emerging benefits associated with such microprocessor feet (MPFs) include improved biomechanical performance during the negotiation of ramps and stairs1–6 increased toe clearance in swing,4,6 reduced peak pressures against the residual limb1,2 and increased prosthetic mobility.7,8

1Hanger Institute for Clinical Research and Education, Austin, TX, USA
2Department of Physical Medicine and Rehabilitation, University of Utah Health, Salt Lake City, UT, USA
3Department of Biomechanics, University of Nebraska at Omaha, Omaha, NE, USA

Corresponding author:
Phillip M Stevens, Hanger Institute for Clinical Research and Education, 10910 Domain Dr, Austin 78758, TX, USA.
Email: pstevens@hanger.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
However, much of the literature supporting the use of MPF’s has been supported by product manufacturers, and derived from measurements taken in controlled laboratory environments. Independent analyses of such feet in community settings have been limited. Prosthetic mobility, often measured with instruments such as Prosthesis Evaluation Questionnaire (PEQ) or Prosthetic Limb Users Survey of Mobility (PLUS-M), is closely related to the overarching construct of physical function. Physical function has been described as one of many health indicators that can be used to monitor self-reported health and track rehabilitation goals among prosthetic users. The domain of physical function plays a pivotal role in prosthetic rehabilitation. Prior studies have shown that poor physical function when assessed with performance measures is associated with increased risk of falls, mortality, and morbidity among lower limb prosthesis users. However, very limited evidence exists examining the relationship of MPFs to improved physical function when measured with instruments such as the PROMIS-PF (Patient-Reported Outcomes Measurement Information System - Physical Function) or PEQ. The PROMIS-PF was recently developed to evaluate one’s capacity to complete various physical tasks, and was designed to overcome psychometric limitations such as floor/ceiling effects, responder burden, and lack of responsiveness.

The PEQ is a well-validated population-specific patient reported instrument outcome assessing several constructs related to quality of life among users of lower limb prostheses including prosthesis function, mobility, psychosocial considerations and well-being. While the individual items of the PEQ have not been validated for independent use, the breadth of the measure provides a number of individual test items spanning a diverse range of specific activities, environments and considerations that have received some measure of psychometric validation.

The primary purpose of this study was to determine the impact of MPF upon physical function as measured with the PROMIS-PF among transtibial prosthesis users as they transitioned to the use of a number of commercially available MPFs while maintaining their original socket fit. The secondary aim of this study was to provide preliminary findings on the impact of MPF upon back pain, residual limb pain, and hill ascent and descent using single-item questions from the Prosthesis Evaluation Questionnaire (PEQ). It was hypothesized that the transition from a non-MPF to an MPF would be associated with improvements in physical function as measured by a custom short form of the PROMIS-PF.

**Methods**

**Study design**

Records beginning in July 2019 through February 2021 from cases within a national provider of lower limb prostheses were assessed for eligibility. Patient cases were eligible if the patient was an established non-MPF transtibial prosthesis user and had a written prescription from a physician on file to transition into an MPF. In order to limit fit confounders, individuals were excluded if their socket was also replaced. To address the current hypothesis, patient reported outcomes collected as part of the patient’s evaluation (i.e. prior to receipt of MPF) and at a subsequent follow-up appointment (i.e. after patient had acclimated to the new MPF) were extracted for analysis. After the delivery of the MPF, board-certified prosthetists ensured that the patient’s foot was properly fitted, aligned and adjusted for comfort. Since there were not onsite physical therapists present at the clinic...certified prosthetists provided training to patients on how to ambulate with the MPF. The current retrospective analysis of patient outcomes was approved by the Western Copernicus Group Investigational Review Board (Protocol # 20170059). Patients were exempt from informed consent. This study conforms with the STROBE guidelines.

**Participants**

Individuals included in this analysis were adults 18 years and older with lower limb amputation. There were no exclusions based on amputation etiology.

**Endpoint measures**

The endpoint measures in this analysis primarily focused on the results from a custom PROMIS Physical Function (PROMIS-PF) patient reported outcomes questionnaire. A secondary focus included the combination of independent item questions from the PEQ. The PROMIS-PF is a psychometrically validated instrument designed for the general population which can be customized to a targeted subpopulation by selecting relevant and appropriate items. An eight-item PROMIS-PF short form was used in this study with items selected that were tailored towards lower limb prosthesis users. This approach of using a customized PROMIS short form is well documented in previous studies. Scores obtained can be compared to scores derived from other PROMIS physical function questionnaires when using the same item bank (v2.0). The eight items (i.e., PFA9, PFA21, PFA23, PFC6r1, PFA42, PFC41, PFC45r1, PFA56) taken from the PROMIS v2.0 PF item
bank included assessments of bending down to retrieve clothing from the floor, going up and down stairs at a normal pace, going for a walk of at least 15 min, walking a block, carrying a laundry basket up a flight of stairs, transferring in and out of a low, soft couch, transferring off and onto the toilet and getting in and out of a car. Responses to the questions range on a 5-point ordinal scale ranging from “without any difficulty” to “unable to do”. Each response is assigned a 1-5 value, and then all responses are subsequently summed. This raw score is then converted to a normally distributed T-score for subsequent analysis and comparison using the HealthMeasures.net scoring service.

Items taken from the PEQ included assessments of prosthesis fit, prosthesis weight, sitting comfort, residual limb pain, back pain, and the respective abilities to walk both up and down a steep hill. Each item was individually graded on a 5-point ordinal scale with 5 representing a positive response option. Notably, while the original PEQ was comprised of continuous visual analog scales, there have been previous examples of effective use of PEQ questions administered with discrete, ordinal scale responses.22

Independent variables

The main independent variable used was foot type (i.e., non-MPF and MPF). Other demographic variables used to describe the study population included age, sex, cause of amputation, height, weight, time between assessments, and employment status. For time between assessments, outcome pairs were retained for those patients who had experienced between 13 and 120 days between their two assessments. This time window was selected to ensure adequate acclimation to the new prosthetic foot without allowing so much time that changes might be reasonably attributed to factors outside of the prosthesis. Employment status was defined as being currently employed (or student status) or not.

Statistical analysis

Demographic and amputation-related factors were presented at the patient-level for this analysis. Prior to inferential analysis, the final sample was assessed for normality, homoscedasticity, absence of multicollinearity, and outliers. A paired t-test was used to assess the unadjusted differences in PROMIS-PF scores among the non-MPF and MPF. To adjust for the confounding effect that certain demographic and clinical variables may have on this relationship, a linear mixed effect regression model was conducted using the lme4 r package. For the linear mixed effects analysis, MPF technology, gender, age, time between assessment, and etiology (collapsed to vascular disease/diabetes or not) were entered as fixed effects, while the intercept for subjects was entered as a random effect. The likelihood ratio test was used to obtain the p-values for the full model with the main independent variable versus a null model without the main independent variable.24 Adjusted analyses were not conducted for the relationships between the use of MPF and PEQ items. All statistical analyses were performed using R (R Core Team, 2012).

Results

There were 23 patient cases that were found for analysis. Three of the patient cases had follow-up measures outside the inclusion window and were excluded. The remaining 20 patients presented with an average age of 56.65 years with an average of 31.85 days between baseline and follow-up assessments (Table 1). Over 60% of the sample were male (13/20), and the most frequent cause of amputation was vascular disease/diabetes. Subjects used a range of legacy non-MPFs, most of which were consistent with the community ambulation standards of the K3 Medicare Functional Classification Level. The Blatchford Elan was the most frequently utilized MPF (n = 12), but the Proteor Kinnex, Otto Bock Meridium, and Ossur Proprio were also utilized. While all MPF’s were fitted and aligned by board-certified prosthetists, there was no standardized physical therapy associated with the receipt of the new prosthetic feet.

Physical Function

Univariate analysis. Using a paired t-test for analysis, there was a significant increase in PROMIS-PF scores with the use of a MPF compared to those observed with the non-MPF (MPF - non-MPF mean difference: 5.40 ± 1.25; t(19) = 4.31 (p = 0.0004) (Figure 1).

Multivariate analysis. A similar finding was noted with the multivariate analysis. When controlling for confounders, such as age, gender, etiology, and time between assessment, individuals’ PROMIS-PF T-Scores increased by 5.40 points (95% CI [2.88-7.91], χ² (1) =13.64, p = .0002; Table 2).

Prosthesis evaluation questionnaire

Back pain, residual limb pain, and hill ascent and descent. Independent items from the PEQ were used to assess differences between prosthetic foot type across individual constructs (Table 3). With respect to general directionality, all queried items from the PEQ improved with the transition from a non-MPF to a MPF. With respect to the perceived quality of the socket fit, significant improvements were noted with respect to both prosthesis fit (p = .035) and
sitting comfort with the prosthesis ($p < .001$). Improvements with respect to the intensity of back pain were statistically significant ($p = .010$). Significant improvements were observed for both ascent ($p < .001$) and descent ($p < .001$) of steep hills in the MPF conditions. The mean improvements for residual limb pain intensity did not reach a level of statistical significance (Table 3). Improved scores for the perceived weight of the prosthesis in the MPF condition also did not reach a level of statistical significance.

**Figure 1.** PROMIS-PF T-scores significantly improved for patients when using MPFs compared to their non-MPFs ($p = .0004$). MPF = microprocessor foot.

## Discussion

A Cochrane Review on the prescription of prosthetic ankle-foot mechanisms after lower limb amputation observed that most clinical trials on prosthetic ankle foot mechanisms were informed by laboratory data collected in controlled walking environments. They encouraged the use of outcome measures with more ecological validity that took a broader view of mobility including transfers, maintaining balance, the negotiation of stairs and inclines, and walking over environmental obstacles. The data collected in this convenience sample of prosthesis users maintaining their transtibial socket while transitioning from a non-MPF to an MPF provides additional insights beyond the controlled laboratory environments from which much of the evidence to date has relied upon.

Transtibial prosthesis users who transitioned from non-MPFs to MPFs experienced a significant improvement in their physical function score as measured using the PROMIS-PF. The five-point improvement in the PROMIS-PF score far exceeded the recommended range (1.9-2.2) noted as a minimally important difference for improvement found in other sub-populations, suggesting that the transition from a non-MPF to a MPF technology was not only statistically significant but also clinically meaningful. Upon detailed analysis, those items with the greatest improvements in physical function included items reflective of sit-to-stand transfers and stair negotiation followed by bending down to retrieve something from the floor. More modest benefits were also observed with level ground ambulation over sustained times and distances.

The benefits of MPF in stair ascent have been established in several laboratory based clinical trials. The Ossur Proprio MPF has been associated with increased dorsiflexion in stance, improving the positioning of the ipsilateral knee into relative stance flexion to maintain upward and forward momentum. The latter adaptation yields a more even distribution of peak pressures in the socket such that pressure values associated with stair ascent with an MPF better approximate those observed in level ground walking. These biomechanical observations, coupled with increased swing phase dorsiflexion reducing the risk of a stumble on the stair landing, may partially explain the observed improvements to the PROMIS questions, “Are you able to carry a laundry basket up a flight of stairs,” and “Are you able to go up and down stairs at a normal pace.”

The benefits of MPF relative to sit-to-stand transfers from either a low, soft couch or a toilet have not been previously reported. The added ankle dorsiflexion likely permits the users to bring their ipsilateral knee and body center of mass further anterior over their feet to execute such stand-to-sit and sit-to-stand transfers with easier mechanics. This same benefit would appear to assist the retrieval of a dropped item from the floor as the augmented stance dorsiflexion would allow the user to sustain their center of mass over a larger plantar surface area.

Improvements were observed but less pronounced with PROMIS questions related to sustained ambulation on level ground. This is consistent with the observations of Hahn et al with the Ottobock Meridium MPF where improvements were observed with greater frequency during complex gait tasks such as negotiating ramps and uneven terrains (82%-97%) than the more subdued task of level ground ambulation (54%). Delussi et al observed significant reductions in the measured energy costs of ambulation after 90°days with the Proprio MPF. Reductions in energy cost may partially explain the mean improvements associated with the questions related to sustained ambulation of at least 15 min in duration, or a block (100 m) in length.

With respect to the items taken from the PEQ, the constructs associated with the greatest improvement were the navigation of steep hills. Significant improvements were
also observed with respect to socket comfort. Both of these are in alignment with the PROMIS-PF findings related to stair ascent and descent, movements that require the ankle joint to operate in a different range to dissipate excessive forces rather than translating to the limb-socket interface and proximal joint structures.

The improved ability to walk both up a steep hill and down a steep hill with an MPF may be tied to the biomechanics of the MPF. Specifically, the biomechanics of MPF during ramp negotiation have been studied extensively. During ramp ascent, the additional stance phase dorsiﬂexion of the Ossur Proprio MPF reduces the knee hyperextension associated with non-articulating feet, leading to a more favorable knee position to maintain momentum forward and up. In addition, minimum toe clearance values increase 53%-100% in swing phase with the greatest increases associated with increased walking velocities. During ramp descent, the additional ankle plantarﬂexion reduces the ﬂexion moment acting upon the ipsilateral knee, increasing the perceived safety associated with that ambulation environment. With the Blatchford Elan MPF, ramp descent is associated with a relatively quick foot ﬂat followed by a more measured forward shank rotation, reducing the ﬂexion moment acting upon the knee and affording a controlled forward shank progression. Increased minimum toe clearance values have been observed with the Endolite Elan MPF during both ramp ascent and descent. The Proteor Kinnex MPF has been associated with improved socket comfort scores in both standing and walking on both inclined and declined slopes. These cumulative, largely laboratory-based ﬁndings may begin to explain why our

Table 1. Sample Demographics.

| Subject ID | Age (years) | Legacy Foot | MPF | Time Between Assessments (days) | Gender | Height (cm) | Weight (kg) | Cause of Amputation | Employed |
|------------|-------------|-------------|-----|---------------------------------|--------|-------------|-------------|---------------------|----------|
| 1          | 60          | Sierra      | Elan| 14                              | F      | 162.56      | 68.18       | Injury/trauma       | No       |
| 2          | 64          | Echelon     | Elan| 14                              | M      | 172.72      | 110.91      | Vascular Disease/ diabetes | Yes      |
| 3          | 44          | Agilix      | Elan| 14                              | M      | 180.34      | 106.82      | Vascular Disease/ diabetes | Yes      |
| 4          | 70          | Triton      | Elan| 17                              | F      | 162.56      | 63.64       | Infection without diabetes | No       |
| 5          | 57          | Kinterra    | Elan| 19                              | M      | 182.88      | 100.00      | Vascular Disease/ diabetes | No       |
| 6          | 27          | Celsius     | Elan| 21                              | F      | 157.48      | 56.82       | Injury/trauma       | No       |
| 7          | 51          | Maverick    | Elan| 23                              | F      | 167.64      | 81.82       | Infection without diabetes | Yes      |
| 8          | 66          | Echelon     | Elan| 23                              | M      | 165.10      | 66.36       | Vascular Disease/ diabetes | No       |
| 9          | 68          | Trias       | Elan| 36                              | F      | 160.02      | 85.45       | Vascular Disease/ diabetes | No       |
| 10         | 70          | Maverick    | Elan| 44                              | M      | 175.26      | 58.18       | Infection without diabetes | No       |
| 11         | 58          | Odyssey K3  | Elan| 98                              | F      | 160.02      | 85.45       | Other               | Yes      |
| 12         | 69          | Proaxis XC  | Elan| 112                             | M      | 185.42      | 81.82       | Vascular Disease/ diabetes | No       |
| 13         | 70          | RUSH 87 & SACH | Kinnex | 14                          | M      | 167.64      | 96.36       | Vascular Disease/ diabetes | No       |
| 14         | 58          | RUSH Rogue  | Kinnex| 14                         | M      | 185.42      | 104.55      | Vascular Disease/ diabetes | Yes      |
| 15         | 67          | Kinterra    | Kinnex| 33                        | M      | 175.26      | 90.91       | Injury/trauma       | Yes      |
| 16         | 48          | C-Walk      | Meridium| 13                    | M      | 175.26      | 91.82       | Congenital          | No       |
| 17         | 51          | Maverick    | Meridium| 32                     | M      | 175.26      | 75.45       | Vascular Disease/ diabetes | Yes      |
| 18         | 32          | Elite 2     | Meridium| 37                     | M      | 185.42      | 67.27       | Injury/trauma       | No       |
| 19         | 49          | Maverick    | Proprio| 24                    | F      | 172.72      | 115.91      | Injury/trauma       | Yes      |
| 20         | 54          | Kinterra    | Proprio| 35                    | M      | 175.26      | 91.36       | Other              | Yes      |
subjects reported significant reductions in difficulty with their ability to walk both up a steep hill and down a steep hill with their MPF.

Another interesting finding is the improvement in assessment of fit of the prosthesis. All subjects maintained their same socket during the transition to their MPF, yet they reported a significant improvement in their assessment of the fit of their prosthesis once they walked with their MPF. This may be due to a reduction in localized socket pressures described above during slope and stair negotiation and further reported with hydraulic ankle-feet during level ground ambulation. Subjects also reported significant improvement in sitting comfort. This may reflect the ability of MPF options to yield into both dorsiflexion and plantarflexion to accommodate a range of knee angles with an associated reduction in localized force couples within the socket. While seven of twenty subjects reported a mean decrease in residual limb pain compared to only four reporting a mean increase in limb pain, the mean improvement of the cohort failed to reach statistical significance. This may suggest that socket discomfort is not always perceived as intense residual limb pain.

Somewhat surprisingly, improvements related to pain intensity were less pronounced and failed to reach statistical significance. Statistical improvements were, however, noted with respect to sitting comfort. This may suggest that there is increased discomfort with non-MPF, but it does not cross into the threshold of being considered painful. Counter to our hypothesis, the transition to the use of heavier MPFs was not perceived as increasing the weight of the prostheses. Rather, the weight of the device with the MPF was viewed more favorably than that associated with the legacy foot, though this difference failed to reach significance. This trend in reduced perceived weight may reflect increased minimum toe clearance values associated with MPF and the decreased need for compensatory gait mechanisms to achieve adequate swing phase clearance in the presence of augmented swing phase dorsiflexion. Our findings conflict with the reports of Kaluf et al where subjects identified the increased weight of the Proteor Kinnex MPF as one of their primary “dislikes” relative to the non-MPF. However, it should be noted that the most commonly utilized MPF in our sample, the Elan, weighs 20% less than the Proteor Kinnex.

| Table 2. Linear mixed effect model for PROMIS-PF. |
|-------------------------------|----------------|-----------------|-----------------|----------------|
| Variables                      | Estimate      | Lower bound    | Upper bound     |
| MPF Non-MPF                   | –             | –               | –               |
| MPF                           | 5.40          | 2.88            | 7.91            |
| Gender                        |               |                 |                 |
| Female                        | –             | 0.27            | –               |
| Male                          | –             | –               | –               |
| Age                           | –             | -0.02           | 0.21            |
| Etiology                      |               |                 |                 |
| Non-dysvascular/Non-diabetic   | –             | 0.38            | –               |
| Vascular Disease/diabetes     | 0.38          | 0.05            | 4.97            |
| Time between assessments      | 0.03          | 0.05            | 0.10            |

| MPF = microprocessor foot. |

Table 3. Mean differences among PEQ items with Non-MPF and MPF.

| PEQ item number | PEQ construct       | Non-MPF Mean ± SD | MPF Mean ± SD | Mean difference (95% CI) | p value |
|-----------------|---------------------|-------------------|----------------|-------------------------|---------|
| Group 2- I      | Residual limb pain  | 3.50 ± 1.20       | 3.78 ± 0.94    | 0.28(-0.31, 0.86)       | .331    |
| Group 1- B      | Prosthesis fit*     | 3.47 ± 1.17       | 3.95 ± 0.91    | 0.47(0.04, 0.91)        | .035    |
| Group 1- C      | Prosthesis weight   | 3.11 ± 0.57       | 3.63 ± 1.01    | 0.53(-0.04, 1.09)       | .066    |
| Group 1- E      | Sitting comfort*    | 3.16 ± 0.69       | 4.00 ± 0.89    | 0.84(0.47, 1.21)        | <.001   |
| Group 2- O      | Back pain*          | 3.38 ± 1.20       | 4.31 ± 0.60    | 0.94(0.25, 1.62)        | .01     |
| Group 4- E      | Hill ascent*        | 2.44 ± 0.92       | 3.78 ± 0.73    | 1.33(0.74, 1.92)        | <.001   |
| Group 4- F      | Hill descent*       | 2.44 ± 0.78       | 3.94 ± 0.94    | 1.50(0.90, 2.10)        | <.001   |

Individual items from the PEQ; PEQ = Prosthesis Evaluation Questionnaire; MPF = microprocessor foot; Non-MPF = non-microprocessor foot; SD = standard deviation; CI = confidence interval; * = significant at p < 0.05.
The significant improvement in back pain intensity associated with the transition to an MPF was not anticipated. The biomechanical rationale for this observation is unclear, but may be related to the improved swing phase clearance associated with MPFs and a reduced need to utilize compensatory gait strategies at the hips and low back. This apparent relationship between MPFs and low back pain warrants further investigation and research.

There are a number of limitations associated with this research. While patient-reported feedback was collected from users of four commonly utilized and commercially available MPFs, the sample sizes were insufficient to draw meaningful conclusions related to the comparative effectiveness of different MPF models, and therefore further subanalysis comparing groups were not performed. Future work should consider exploring the impact of MPF models on patient outcomes. As a retrospective analysis of clinical data, it is challenging to control the quality of alignment or settings of the MPFs used in this study. Rather, this study represents an analysis of patient reported outcomes in an ecologically representative sample of patients receiving care from a number of different clinicians across the United States. Notably, all clinicians are required to take a minimum level of continuing education to maintain their status, as well as targeted courses for providing the care associated with these MPFs. While refinements in alignment and settings may have led to additional improvements in certain metrics, our findings represent the realities of the alignments and settings observed in a cross-sectional analysis of patient fittings as they occurred in traditional patient care environments rather than controlled laboratory settings. Subsequently, stronger benefits may be possible with enhanced clinician training.

Another limitation to this study is that the domains of pain, stair ascent and decent were measured using single-item questions extracted from the PEQ in an approach that has not been validated. Nevertheless, the intention of our secondary aim was to provide a preliminary assessment of the impact of MPF to improve back pain. Future studies should explore this relationship using standardized, validated instruments that may be able to reinforce the current findings. Finally, while patients are known to occasionally reject new components, our retrospective screening efforts did not identify any individuals who rejected their MPF at delivery. This may represent a possible sampling bias within our retrospective screening methodology.

Conclusion

This study supports previous findings conducted in controlled laboratory walking environments showing benefits associated with microprocessor feet (MPFs). These known benefits include: improved biomechanical performance during the negotiation of ramps and stairs, increased toe clearance in swing, reduced peak pressures against the residual limb within the socket and increased prosthetic mobility. Additionally, this study demonstrates how MPFs interact outside of the laboratory when the only prosthetic variable was the transition from non-MPF to MPF. Transtibial prosthesis users who transitioned from non-MPFs to MPFs experienced a significant improvement in their physical function score as measured by the PROMIS-PF. In addition, back pain, residual limb pain, and hill ascent and descent showed improved scores from the independent items taken from the PEQ. Observations from this study can inform clinical decision making surrounding known clinical benefits of MPF technology.

Contributorship

PS and EW design and conceived the study. PS conducted the literature review and wrote the first draft. DE and SW were involved in gaining ethical approval and data analysis. DE and VS were involved in data reduction. All authors critically revised, edited, and approved the final version of the manuscript.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Guarantor

PS.

ORCID iDs

Phillip M Stevens https://orcid.org/0000-0003-3488-0707
Dwiesha L England https://orcid.org/0000-0002-4274-5356

References

1. Agrawal V, Gailey R, O’Toole C, et al. Influence of gait training and prosthetic foot category on external work symmetry during unilateral transtibial amputee gait. Prosthetics Orthot Int 2013; 37(5): 396–403.
2. Alimusaj M, Fradet L, Braatz F, et al. Kinematics and kinetics with an adaptive ankle foot system during stair ambulation of transtibial amputees. Gait Posture 2009; 30(3): 356–363.
3. Fradet L, Alimusaj M, Braatz F, et al. Biomechanical analysis of ramp ambulation of transtibial amputees with an adaptive ankle foot system. Gait & Posture 2010; 32(2): 191–198.
4. Rosenblatt NJ, Bauer A, Rotter D, et al. Active dorsiflexing prostheses may reduce trip-related fall risk in people with...
transtibial amputation. *J Rehabil Res Dev* 2014; 51(8): 1229–1242.

5. Struchkov V and Buckley JG. Biomechanics of ramp descent in unilateral transtibial amputees: comparison of a microprocessor-controlled foot with conventional ankle-foot mechanisms. *Clin Biomech* 2016; 32: 164–170.

6. Riveras M, Raveria E, Ewins D, et al. Minimum toe clearance and tripping probability in people with unilateral transtibial amputation walking on ramps with different prosthetic designs. *Gait & Posture* 2020; 81: 41–48.

7. Kaluf B, Cox C and Shoemaker E. Hydraulic-and microprocessor-controlled ankle-foot prostheses for limited community ambulators with unilateral transtibial amputation: pilot study. *JPO: J Prosthetics Orthotics* 2021; 29: 294–303.

8. Wurdeman SR, Stevens PM and Campbell JH. Mobility analysis of AmpuTees (MAAT 5): impact of five common prosthetic ankle-foot categories for individuals with diabetic/dysvascular amputation. *J Rehabil Assist Technol Eng* 2019; 6: 205568318820784.

9. Delussu AS, Brunelli S, Paradisi F, et al. Assessment of the effects of carbon fiber and bionic foot during overground and treadmill walking in transtibial amputees. *Gait & Posture* 2013; 38: 876–882.

10. Wolf SI, Alimusaj M, Fradet L, et al. Pressure characteristics at the stump/socket interface in transtibial amputees using an adaptive prosthetic foot. *Clin Biomech* 2009; 24(10): 860–865.

11. Legro MW, Reiber GD, Smith DG, et al. Prosthesis evaluation questionnaire for persons with lower limb amputations: assessing prosthesis-related quality of life. *Arch Phys Med Rehab* 1998; 79(8): 931–938.

12. Hafner BJ, Gaunaud IA, Morgan SJ, et al. Construct validity of the prosthetic limb users survey of mobility (PLUS-M) in adults with lower limb amputation. *Arch Phys Med Rehab* 2017; 98(2): 277–285.

13. Amtmann D, Morgan SJ, Kim J, et al. Health-related profiles of people with lower limb loss. *Arch Phys Med Rehab* 2015; 96(8): 1474–1483. DOI: 10.1016/j.apmr.2015.03.024.

14. Miller MJ, Morris MA, Magnusson DM, et al. Psychosocial factors influence physical activity after dysvascular amputation: a convergent mixed-methods study. *PM&R* 2021; 13(7): 737–745.

15. Christiansen CL, Fields T, Lev G, et al. Functional outcomes after the prosthetic training phase of rehabilitation after dysvascular lower extremity amputation. *PM&R* 2015; 7(11): 1118–1126. DOI: 10.1016/j.pmrj.2015.05.006.

16. Pauley T, Devlin M and Madan-Sharma P. A single-blind, cross-over trial of hip abductor strength training to improve Timed Up & Go performance in patients with unilateral transfemoral amputation. *J Rehabil Med* 2014; 46(3): 264–270. DOI: 10.2340/16501977-1270.

17. Dite W, Connor HJ and Curtis HC. Clinical identification of multiple fall risk early after unilateral transfemoral amputation. *Arch Phys Med Rehab* 2007; 88(1): 109–114. DOI: 10.1016/j.apmr.2006.10.015.

18. National Institutes of Health. PROMIS—Instrument development and psychometric evaluation scientific standards. Bethesda, MD: National Institutes of Health, 2012.

19. Hafner BJ and Askew RL. Physical performance and self-report outcomes associated with use of passive, adaptive, and active prosthetic knees in persons with unilateral, transfemoral amputation: Randomized crossover trial. *J Rehabil Res Develop* 2015; 52(6): 677–700.

20. Cella D, Gershon R, Lai JS, et al. The future of outcomes measurement: item banking, tailored short-forms, and computerized adaptive assessment. *Qual Life Res* 2007; 16(1): 133–141.

21. England DL, Miller TA, Stevens PM, et al. Assessment of a nine-item patient-reported outcomes measurement information system upper extremity instrument among individuals with upper limb amputation. *Am J Phys Med Rehab* 2021; 100(2): 130–137.

22. Wurdeman SR, Stevens PM and Campbell JH. Mobility Analysis of AmpuTees (MAAT I): Quality of life and satisfaction are strongly related to mobility for patients with a lower limb prosthesis. *Prosthetics Orthotics International* 2018; 42(5): 498–503.

23. Bates D, Sarkar D, Bates MD, et al. The lme4 package. *R Package Version* 2007; 2(1): 74.

24. Winter B. Linear models and linear mixed effects models in R with linguistic applications, 2013. arXiv preprint arXiv: 1308.5499.

25. Hofstad CJ, van der Linde H, Van Limbeek J, et al. Prescription of prosthetic ankle-foot mechanisms after lower limb amputation. *Cochrane Database Syst Rev* 2004; 2010(1): CD003978.

26. Lee AC, Driban JB, Price LL, et al. Responsiveness and minimally important differences for 4 patient-reported outcomes measurement information system short forms: physical function, pain interference, depression, and anxiety in knee osteoarthritis. *The J Pain* 2017; 18(9): 1096–1110.

27. Hahn A, Sreckovic I, Reiter S, et al. First results concerning the safety, walking, and satisfaction with an innovative, microprocessor-controlled four-axes prosthetic foot. *Prosthet Orthot Int* 2018; 42(3): 350–356.

28. Portnoy S, Kristal A, Gefen A, et al. Outdoor dynamic subject-specific evaluation of internal stresses in the residual limb: Hydraulic energy-stored prosthetic foot compared to conventional energy-stored prosthetic feet. *Gait & Posture* 2012; 35(1): 121–125.